Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors
AbstractPurpose of ReviewImmune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will benefit from immunotherapy.Recent FindingsThe safety and tolerability of new interleukin(IL)-2 formulations, IL-15 super agonist, and PEGylated IL-10 have been evaluated in early phase clinical trials with promising efficacy data, both as monotherapy and in combination with ICI. Larger studies focusing on the efficacy of these combinations are ongoing. Personalized neoantigen-based cancer vaccines, enabled by improvements in sequencing computational capabilities, have been proven to be feasible, safe, and able to trigger a consistent vaccine-specific immune response in cancer patients.SummaryNew pharmacologically modified recombinant cytokines and personalized neoantigen-based vaccines may turn these approaches into powerful tools for effective combination immunotherapy.
CONCLUSIONS: Simultaneous CRC and CRLM resections seem to be safe when patients are carefully selected, also considering the risk of recurrence concerning oncologic outcomes. The pre-planning of simultaneous resection is mandatory to plan trocar positioning, procedure sequencing, and patient position. PMID: 32490901 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Ben Newland, Carmine Varricchio, Yvonne Körner, Franziska Hoppe, Christian Taplan, Heike Newland, Dimitri Eigel, Giusy Tornillo, Dagmar Pette, Andrea Brancale, Petra B. Welzel, F. Philipp Seib, Carsten Werner
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhuodong Chai, Chao Teng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han, Lifang Yin
CONCLUSION: a Navigation Program was developed adapted to the Brazilian reality, and attributions of the navigators were created. PMID: 32491120 [PubMed - in process]
Publication date: Available online 3 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Houhe Liu, Yusi Quan, Xinlin Jiang, Xiaotian Zhao, Yi Zhou, Jijun Fu, Lingran Du, Xiaoya Zhao, Jing Zhao, Lu Liang, Di Yi, Yugang Huang, Guodong Ye
Publication date: Available online 3 June 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Hui-Min Wang, Ai-Jun Wang, Pei-Xin Yuan, Jiu-Ju Feng
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC03589K, CommunicationLongbing Ling, Haizhou Yu, Muhammad Ismail, Yan-Ping Zhu, Yuan Du, Junhui Qi An amphiphilic dimeric-podophyllotoxin (PODO) phospholipid was synthesized to assemble into liposomes as a combination of prodrug and nanocarriers. Results have demonstrated cell membrane-like delivery system possessed an improved cellular uptake... The content of this RSS Feed (c) The Royal Society of Chemistry
Authors: Cheng J, Yang A, Cheng S, Feng L, Wu X, Lu X, Zu M, Cui J, Yu H, Zou L Abstract BACKGROUND MicroRNAs (miRNAs) are attracting substantial interest as promising noninvasive biomarkers for gastric cancer (GC). Our study aimed to identify circulating miRNAs that are potential noninvasive markers for precancerous lesions and early gastric cancers (EGCs). MATERIAL AND METHODS Plasma specimens were obtained from 58 gastritis subjects, 54 patients with precancerous lesions, and 38 EGC patients for study. RESULTS Significant differences in the plasma expression levels of miR-19a-3p, miR-22-3p, miR-146a-5p, and miR-483-5p (all P
For example, does transporting patients with cancer from Site A to Site B count as clinical volunteer experience? This is assuming that the driver is in direct contact with the patients. What are some other examples of gaining clinical exposure that are unheard/unrealized of? This will greatly help students such as myself in their gap-years working in non-clinical jobs needing to gain more volunteer experience! For my particular case, I am seeking for an opportunity to gain ~80 hours... What are Some Examples of NonTraditional Ways of Earning Clinical Volunteer Experience?
Conclusions: The combination of currently used risk stratification systems with detailed characterization of MLNs may improve the predictive accuracy for recurrence/progression in N1 PTC patients. PMID: 32487777 [PubMed - in process]